Trial Profile
A Phase II Study of MRI Based Functional Imaging for the Evaluation of Bone Metastasis in Men With Castrate Resistant Prostate Cancer Receiving XL184
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Pharmacokinetics
- 16 Feb 2019 Results of the final analysis, presented at the 2019 Genitourinary Cancers Symposium
- 01 Feb 2019 Status changed from active, no longer recruiting to completed.
- 02 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.